New study seeks to predict which newborns need repeat jaundice treatment

NCT ID NCT07694635

Not yet recruiting Knowledge-focused Sponsor: Haseki Training and Research Hospital Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 14, 2026 · Updated 2 times

Summary

This study follows 300 newborns treated with light therapy for jaundice to find clues that predict whether jaundice will come back. Researchers will check blood bilirubin levels, feeding patterns, and other factors. The goal is to help doctors decide when it's safe to stop treatment and send babies home without needing another hospital stay.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors identify which newborns are at risk for jaundice returning after light therapy, allowing safer discharge and fewer repeat treatments.
What could go wrong: This is an observational study, so it does not test a new treatment. The findings may not apply to all hospitals or newborns, and the predictors identified may not be strong enough to change practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEONATAL HYPERBILIRUBINEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hyperbilirubinemia Hyperbilirubinemia, Neonatal Jaundice, Neonatal transient familial neonatal hyperbilirubinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEONATAL HYPERBILIRUBINEMIA REBOUND HYPERBILIRUBINEMIA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

University of Health Sciences, Haseki Training and Research Hospital

Istanbul, Sultangazi, 34265, Turkey (Türkiye)

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.